Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576119 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects
A Phase 1 study, sponsored by ViiV Healthcare.
- Terminated
- Registry status
- Phase 1
- Development phase
- 315
- Enrollment target
NCT02576119 is a Phase 1 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 315 participants.
The verdict
NCT02576119, a Phase 1 study, was terminated before completion, sponsored by ViiV Healthcare.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 315 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the effect of multiple doses of BMS-955176 on the QT interval corrected with Fridericia's method (QTcF) in healthy subjects.
Interventions
- DRUG BMS-955176, Placebo (Part 1)
- DRUG BMS-955176, Moxifloxacin, Placebo (Part 2)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2015-10-19 |
| Est. Completion | 2016-10-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576119
The ClinicalTrials.gov registry entry for NCT02576119 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 315 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-955176, Placebo (Part 1) is the first listed.
NCT02576119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02576119 about?
NCT02576119 is a clinical study titled "A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects". The purpose of the study is to determine the effect of multiple doses of BMS-955176 on the QT interval corrected with Fridericia's method (QTcF) in healthy subjects.
What is the current status of trial NCT02576119?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 315 participants. The study started on 2015-10-19. Estimated completion is 2016-10-14.
What interventions are being tested in trial NCT02576119?
The interventions under investigation include: BMS-955176, Placebo (Part 1) (DRUG), BMS-955176, Moxifloxacin, Placebo (Part 2) (DRUG).
Who is sponsoring clinical trial NCT02576119?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.